Key Takeaways
- The Lung Cancer Research Foundation is expanding its research advocate groups.
- The group is made up of lung cancer patients and survivors.
- The advocates will help find new and innovative research for lung cancer.
News
Article
Lung Cancer Research Foundation Announces Expansion of its Research Advocate Group
Author(s):
The group is made up of lung cancer patients and survivors.
Stock.adobe.com
Nonprofit organization The Lung Cancer Research Foundation (LCRF) announced the expansion of its research advocates.1 This group helps identify new and innovative areas of research in lung cancer and helps provide funding. The advocates are made up of lung cancer patients and survivors and helps bring the unique patient experience to the forefront of the group’s activities.
How can patient advocates drive research funding?
In a press release, the LCRF’s chief scientific officer Dr. Antoinette Wozniak said, “Patient involvement in LCRF's research grant process is a critical component to identifying areas of unmet need and helping to identify the most promising projects to fund. With their lived experience and input, they ensure that we are investing in projects that have the greatest chance of making an impact on lung cancer and patient outcomes."
Maggie McCloskey is one of the new advocates. In the same press release, she said, “As a lung cancer survivor, I have experienced firsthand how vital research is—not just in developing new treatments, but in giving me hope for the future. Advances in targeted therapies and immunotherapy have extended lives and improved quality of life for people like me. Research is not just about science—it is about creating more tomorrows for patients and their families. As a research advocate, I am proud to help bring that hope to others through research funded by the Lung Cancer Research Foundation."
Sydney Barned, MD, one of the other new advocates, also said, “I joined LCRF as a Patient Research Advocate because our voices are vital in shaping research that truly reflects the needs of patients. We are the ones living with the disease, and our experiences can drive more meaningful, patient-centered solutions that improve care and outcomes for everyone facing lung cancer.”
In September of last year, the LCRF announced a partnership with Bayer Pharmaceuticals.2 Together, the two organizations funded two research grants for HER2 mutation and other HER2 alterations.
In a press release issued at the time, LCRF scientific advisory board chair Kathryn O’Donnell, PhD, said, “LCRF is delighted to collaborate with Bayer to identify and support outstanding lung cancer research projects that will help develop treatments for this specific set of lung cancers. Expanding the treatment options available to patients affected by HER2 mutations or alterations is an important and exciting area in lung cancer research."
In the same press release, Abedali Majdi, MD, head of global medical affairs, precision oncology, and pipeline at Bayer’s pharmaceutical division, also said, “We are delighted to encourage and support groundbreaking research via this new LCRF initiative. This collaboration underscores our ongoing commitment to patients living with lung cancer, and our unwavering drive to advance precision oncology in disease areas with the highest unmet needs.”
Sources
- Lung Cancer Research Foundation Expands Research Advocates. Lung Cancer Research Foundation. June 10, 2025. https://www.prnewswire.com/news-releases/lung-cancer-research-foundation-expands-research-advocates-302477647.html
- Lung Cancer Research Foundation Announces New Research Collaboration with Bayer Pharmaceuticals. Lung Cancer Research Foundation. September 5, 2024. Accessed June 10, 2025. https://www.prnewswire.com/news-releases/lung-cancer-research-foundation-announces-new-research-collaboration-with-bayer-pharmaceuticals-302238479.html
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Videos
Related Content
